Mental state: clinically important response in mental state BPRS score >30% change · patients with schizophrenia
Clozapine: low dose (150 mg/day to 300 mg/day) showed no clear difference in mental state: clinically important response in mental state BPRS… compared with standard dose (301 mg/day to 600 mg/day) (low certainty).
1 finding from 1 review
Functioning: clinically important change in general functioning, as defined by individual studies · patients with schizophrenia
1 finding from 1 review
Adverse effect: clinically important adverse effect (weight ‐ BMI) · patients with schizophrenia
1 finding from 1 review
Service use: time to hospitalisation · patients with schizophrenia
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
1 finding from 1 review
Incidence of asymptomatic bacteriuria · postoperative kidney transplant patients
It is very uncertain whether urinary catheter removal < 5 days postoperatively changes incidence of asymptomatic bacteriuria compared with urinary catheter removal ≥ 5 days postoperatively (very low certainty).
1 finding from 1 review
Incidence of symptomatic UTI · postoperative kidney transplant patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of major urological complications · postoperative kidney transplant patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death from any cause · patients requiring blood transfusion (children with malaria and adults with a traumatic injury)
It is very uncertain whether long‐stored ('older') PRBC (≥ 21 days of storage) changes death from any cause compared with short‐stored (fresh) PRBC (< 21 days of storage) (very low certainty).
1 finding from 1 review
Transfusion‐related acute lung injury ‐ not measured · patients requiring blood transfusion (children with malaria and adults with a traumatic injury)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Postoperative infections ‐ not measured · patients requiring blood transfusion (children with malaria and adults with a traumatic injury)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Post‐injury coagulopathy ‐ not measured · patients requiring blood transfusion (children with malaria and adults with a traumatic injury)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Multiple organ failure post‐injury ‐ not measured · patients requiring blood transfusion (children with malaria and adults with a traumatic injury)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event (Hyperkalaemia) ‐ not measured · patients requiring blood transfusion (children with malaria and adults with a traumatic injury)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event (Metabolic acidosis) · patients requiring blood transfusion (children with malaria and adults with a traumatic injury)
1 finding from 1 review
Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) showed no clear difference in complete cure, at least 3 months after the end of treatment compared with placebo (3 tablets/4 times a day (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) probably leads to higher adverse effects (number of participants who had at least one adverse… compared with placebo (3 tablets/4 times a day (moderate certainty).
1 finding from 1 review
Recurrence · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) showed no clear difference in recurrence compared with placebo (3 tablets/4 times a day (low certainty).
1 finding from 1 review
Clinical relapse · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found